Drug Landscape ›
Ciclosporine A ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 12
Most-reported reactions
Leukaemia Recurrent — 2 reports (16.67%) Lung Infection — 2 reports (16.67%) Acidosis — 1 report (8.33%) Anaemia — 1 report (8.33%) Anaphylactic Reaction — 1 report (8.33%) Aphthous Ulcer — 1 report (8.33%) Arthritis — 1 report (8.33%) Blood Cholesterol Increased — 1 report (8.33%) Blood Creatine Increased — 1 report (8.33%) Blood Pressure Increased — 1 report (8.33%)
Source database →
Ciclosporine A in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ciclosporine A approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Ciclosporine A in United States?
Technische Universität Dresden is the originator. The local marketing authorisation holder may differ — check the official source linked above.